摘要
目的:评价肝动脉介入联合靶向治疗结肠癌肝转移的疗效及药物不良反应。方法:78例结肠癌肝转移患者随机分为干预组和对照组,干预组(42例)应用肝动脉介入((TACE))联合靶向治疗方案治疗,对照组(36例)单纯采用肝动脉介入治疗(TACE)方案治疗。结果:干预组和对照组的近期有效率分别为80.9%和55.6%,差异有显著性意义(P﹤0.05)。治疗后0.5、1、2、3、5年生存率,干预组为94.3%,68.8%,33.7%,18.4%,10.3%,对照组为84.2%,54.6%,19.6%,8.1%,2.5%,两组之间差异有显著性意义(P﹤0.05)。在药物不良反应及并发症方面两组之间无显著性差异。结论:应用肝动脉介入联合靶向治疗结肠癌肝转移,优于单纯肝动脉介入治疗的效果。
Objective： To evaluate the hepatic artery interventional therapy combined with targeted therapy efficacy and adverse drug reactions in the treatment of colon cancer liver metastasis. Method： 78 cases of colon cancer patients with liver metastases were randomly divided into intervention group and control group, intervention group application hepatic artery intervention （TACE ） combined targeting treatment. Control group were treated with artery interventional therapy （ TACE ）. Results： The intervention group and control group response rate was 80.9% and 55.6% respectively, the difference was significant （P 〈0.05 ）. The survival rate after treatment 0.5,1,2,3,5 years, the intervention group was 94.3%, 68.8%, 33.7%, 18.4%, 10.3%, the control group was 84.2%, 54.6%, 19.6%, 8.1%, 2.5%. There was significance different between the two groups （ P 〈0.05 ）. No significant differences in adverse drug reactions and complications between the two groups. Conclusion： The effect of hepatic artery interventional therapy combined with targeted therapy of colon cancer patients with liver metastases, is superior to simple hepatic artery interventional therapy.
出处
《河北医学》
CAS
2013年第4期546-549,共4页
Hebei Medicine
关键词
结肠癌肝转移
肝动脉介入治疗
靶向治疗
Colon cancer liver metastases
Hepatic artery interventional treatment
Targeted therapy
